KRAS G12S
Clinical trials for KRAS G12S explained in plain language.
Never miss a new study
Get alerted when new KRAS G12S trials appear
Sign up with your email to follow new studies for KRAS G12S, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-11818 in people with advanced cancers that have a KRAS mutation, including lung, pancreatic, and colorectal cancers. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. Abou…
Matched conditions: KRAS G12S
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New immunotherapy option for High-Risk pancreatic cancer patients
Disease control AVAILABLEThis expanded access program offers ELI-002 7P, an immunotherapy, to pancreatic cancer patients with specific KRAS or NRAS gene mutations who have had their tumor removed but are at high risk of the cancer coming back. The treatment aims to stimulate the immune system to target a…
Matched conditions: KRAS G12S
Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC